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Background: In the Mitra plus study of prevention of mother-to-child transmission of HIV-1, which included 501
women in Dar es Salaam, Tanzania, triple antiretroviral therapy (ART) was given from late pregnancy throughout
breastfeeding up to 6 months postnatally. Here we report findings in a sub-cohort of women with ≤200 CD4cells/μL at
enrolment who were continued on ART for life and followed up during 24 months after delivery to determine virologic
and immunologic responses, drug resistance and mortality.
Methods: Blood samples for viral load and CD4 counts testing were collected at enrolment and at 3, 6, 12 and 24 months
postpartum. HIV drug resistance testing was performed at 12 months. Data analysis included descriptive statistics and
multivariate analysis using Generalized Estimated Equations of 73 women with at least two postpartum assessments.
The mortality analysis included 84 women who had delivered.
Results: The proportion of women with a viral load ≥400 copies/mL was 97% (71/73) at enrolment, 16% (11/67), 22%
(15/69), 61% (36/59) and 86% (48/56) at 3, 6, 12 and 24 months postpartum, respectively. The proportion of women with
immunologic failure was 12% (8/69), 25% (15/60) and 41% (24/58) at 6, 12 and 24 months, respectively. At 12 months,
drug resistance was demonstrated in 34% (20/59), including 12 with dual-class resistance. Self-report on drug adherence
was 95% (64/68), 85% (56/66), 74% (39/53) and 65% (30/46) at 3, 6, 12 and 24 months, respectively. The mortality rate
was 5.9% (95% CI 2.5-13.7%) at 24 months. The probability of virologic and immunologic failure was significantly higher
among women who reported non-perfect adherence to ART at month 24 postpartum.
Conclusions: Following an initial decline of viral load, virologic failure was common at 12 and 24 months postpartum
among women initiated on ART for life during pregnancy because of low CD4 cell counts. A high proportion of viremic
mothers also had resistance mutations. However, at 24 months follow-up, the mortality rate was still fairly low. Continuous
adherence counseling and affordable means of monitoring of the virologic response are crucial for successful implementation
of the WHO Option B+ guidelines to start all HIV-infected pregnant women on ART for life.
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By the end of 2011, women made up 58% of the estimated
23.5 million people living with HIV infection in sub-Saharan
Africa (SSA), home to 92% of pregnant women living
with HIV worldwide [1]. The proportion of HIV-infected
pregnant women in SSA who received antiretroviral (ARV)
drugs for prevention of mother-to-child transmission of
HIV (PMTCT) was 64% in 2012 [2]. At the end of 2012,
59% of pregnant women in the 21 Global Plan priority
countries in SSA who were eligible for antiretroviral therapy
(ART) received it for their own health [3]. Programs for
PMTCT of HIV are often entry points for ART, hence it
is important to understand the sustainability, and virologic
and immunologic treatment outcomes among women initi-
ated on life-long ART during pregnancy.
In Tanzania the national HIV prevalence among
women 15–49 years of age is 6.2%, but higher in Dar es
Salaam, 6.9% [4]. The scale-up of PMTCT has been
quite successful in Tanzania leading to a significant re-
duction in the number of infected infants, from 42,000
in 2001 to 14,000 in 2012. In 2012, 77% of the 97,000
HIV-infected pregnant women in need of PMTCT were
enrolled in a PMTCT program. The main challenge is
the drop-out from PMTCT in late pregnancy and post-
partum [2]. So far PMTCT services are provided in 93%
of reproductive and child health clinics (RCH) [5], 98%
of pregnant women attend RCH at least once, 43% make
at least 4 visits, 85% access HIV testing services but as
high as 48% deliver at home [6]. In low-income coun-
tries like Tanzania where replacement feeding and cae-
sarean sections are uncommon practices, MTCT rates of
HIV can be reduced to 5% or less, when ARV prophy-
laxis is given during the later part of the pregnancy,
delivery and breastfeeding [7-17].
The World Health Organization (WHO) estimates that
pregnant women with CD4 counts ≤ 350 cells/μL account
for about 38% of all HIV-infected pregnant women and
for up to 85% of MTCT of HIV [18]. There is convincing
evidence of improved outcomes in adults if life-long ART
is started at a CD4 count of ≤350 cells/μL [19,20] instead
of at ≤200 cells/μL used earlier [21]. The 2010 WHO
PMTCT guidelines for low-income countries recom-
mended ARV prophylaxis including zidovudine (ZDV) or
combination ARV prophylaxis from as early as 14 weeks
gestation and initiation of continuous ART for maternal
health starting at a CD4 count ≤350 cells/μL [18]. The
2013 WHO PMTCT guidelines recommend that all HIV-
infected pregnant women irrespective of CD4 cell count
should start on lifelong ART (Option B+) [22]. Tanzania
has now begun to implement these new guidelines. This
will have major implications for the Tanzanian health
system including the costs for treatment and monitoring.
The virologic efficacy of ART in SSA is not routinely
monitored by plasma viral load assessment except inresearch environments [23]. Increased scale-up of earlier
ART in low-income countries, high drop-out rates, lack
of laboratory monitoring for treatment failure and few
alternate treatment options raise concerns about un-
detected drug resistance [24].
This study is nested within the Mitra Plus PMTCT
study [8] and aimed at assessing the virologic and im-
munologic treatment outcomes, development of HIV-1
drug resistance and mortality and to check for determi-
nants of treatment failure during the first two years of
follow-up after delivery in a cohort of women on ART
for their own health (CD4 count ≤200 cells/μL at ante-
natal clinic enrollment) in Dar es Salaam, Tanzania.
Methods
Study design and settings
The Mitra Plus was an open-label, non-randomized, pro-
spective cohort study as described previously [8]. Enrolment
into the Mitra Plus study started in April 2004 and ended in
June 2006. The study was conducted at the Dar es Salaam
site previously used for the Petra PMTCT trial [25] and the
Mitra PMTCT study [7].
Study population
The Mitra Plus study population consisted of 501 ARV
treatment naïve HIV-1 infected pregnant women recruited
from four antenatal clinics providing antenatal care ser-
vices, one each from the three municipals of Dar es Salaam
and from the antenatal clinic at the Muhimbili National
Hospital in Dar es Salaam. Prior to enrolment, all women
signed a written consent form to agree or disagree to par-
ticipate. For those who could not read and write, finger-
prints of the right thumb were used. Out of the 501 women
enrolled in the Mitra Plus study, 86 (17%) had a CD4 cell
count of ≤200 cells /μL at enrolment. Among these 86
women, two were lost before delivery (one died and the
other one withdrew from the study), 8 women who were
included in the mortality analysis were excluded from the
treatment response analysis due to early loss to follow-up
before the month 3 assessment. Three women who died
early before they could give a second blood sample post-
delivery were also excluded from the treatment response
analysis. Hence 84 women were included in the mortality
analysis (excluding the two women lost before delivery)
and 73 women were included in the longitudinal analysis
(Figure 1). An additional four women were excluded from
the analysis following their month 6 postpartum visit
when ART was stopped by mistake.
The Mitra Plus study procedure
Enrolled women received normal antenatal care at the
Mitra Plus clinic and were asked to attend Muhimbili
National Hospital for delivery care. ART was initiated at
34 weeks of gestation or earlier in women with CD4 cells
Figure 1 Flow chart of mothers enrolled with CD4 cell count ≤ 200 cell/μL in the Mitra Plus PMTCT study.
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protocol: a combination of ZDV 300 mg twice daily + lami-
vudine (3TC) 150 mg twice daily + nevirapine (NVP)
200 mg lead dose for 14 days which was thereafter in-
creased to 400 mg twice daily. Nelfinavir replaced NVP in
women who developed side effects and towards the end of
enrolment also for those with a CD4 cell count >200/μL.
All women were advised to exclusively breastfeed and to
wean abruptly between 5 and 6 months. ART was stopped
at 6 months except for the subgroup of women with ≤200
CD4 cells/μL at enrolment who continued ART and this is
analyzed in this paper.
Quality of life was determined at enrolment by trained
study doctors using the Karnofsky’s score instrument
[26]. The scale ranges from 0 – 100, where 100 corre-
sponds to optimal quality of life.
Postnatal follow-up of mother-child pairs was done at
weeks 1, 3 and 6, and at months 3, 6, 9, 12, 18, 21 and
24 after delivery. At each visit we performed a clinical
examination of the mothers and children and recorded
adverse events. Blood samples were drawn for complete
blood count, viral load and CD4 cell count assessments
at enrolment, month 3, 6, 12, and 24 postpartum. Drugrefills and drug adherence counseling was done after
every 28 days.
Study nurses conducted home visits to all women who
had missed two consecutive postnatal visits to find out
and record their reasons for non-attendance and to ask
them to come back to the clinic for continuum of care if
willing. At the end of the study follow-up women were
discharged from the study clinic and referred to care
and treatment clinics nearest to their place of residence.
Women came for follow up visits and ARV drug refills
every two weeks followed by weekly visits after gestational
week 36. After delivery women were given a 30-day drug
refill with an appointment after 28 days, providing a two
day-margin for drug refill. A self report on drug adherence
was given at every clinic visit and categorized as “drugs
taken as prescribed yes/no”. Only women who reported
not having missed a single dose during the past month
were regarded as adherent (“taken drugs as prescribed”).
Laboratory methods
Screening for HIV antibodies in the pregnant women
was done at the recruitment site by trained nurse
counselors or health laboratory technologists using the
Ngarina et al. BMC Infectious Diseases  (2015) 15:175 Page 4 of 10CapillusHIV-1/2 assay (Trinity Biotech, Ireland) for ini-
tial testing followed by testing of reactive samples on the
Determine HIV-1/2 assay (Abbott Laboratories). Before
recruitment into the study, a second sample was col-
lected for confirmatory HIV antibody testing by two
consecutive anti-HIV Enzyme-Linked Immunosorbent
Assays (ELISAs), Enzygnost anti-HIV 1/2 Plus ELISA
(Behring, Marburg, Germany) and Vironostika HIV uni-
form II plus O ELISA (Biomerieux, the Netherlands) in
the Department of Microbiology and Immunology at
MUHAS. Sera reactive on both ELISAs were considered
HIV-1 antibody positive. Those that gave discordant re-
sults between the two ELISA were resolved by a Western
blot assay.
Plasma viral load was quantified by the Amplicor HIV-1
Monitor assay version 1.5 (Roche Diagnostics, Indianapolis,
IN, USA). The detection limits of the assay using standard
protocol testing were 400–750,000 copies/mL. In this
study, virologic failure was defined as a detectable HIV-1
RNA load of ≥400 copies/mL at any time during follow up
after three months on ART.
Determination of T-lymphocyte subsets was done
using the SimulSET flow cytometry method (Becton
Dickinson, San Jose, CA, USA) as described previously
[27]. Immunologic failure was defined according to the
WHO criteria: either a fall of CD4 cell count to pre-
therapy baseline or below or a 50% fall of the CD4 cell
count from the on treatment peak value, or persistent
CD4 levels below 100 cells/μL [28].
Drug resistance testing was carried out on plasma
RNA at 12 months after delivery using an in-house
method as described previously [29,30]. Resistance to
nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs)
and protease inhibitors (PIs) was estimated using the
Agence Nationale de Researches Sur le SIDA (ANRS)
algorithm (July 2009, version 18).
Statistical analysis
Data analysis was performed using the STATA software 11
(Stata Corp. College Station, Texas, USA). Mean, median,
interquartile range and standard deviation were used for
descriptive analysis of numerical variables. Frequencies and
percentages were used for categorical variables. Generalized
estimating equations were used to estimate the mean viral
load and CD4 change across 5 measurement occasions
namely: month 0, 3, 6, 12, and 24 and also the association
between virologic and immunologic failure with the base-
line and clinical characteristics at these time points. The
command ‘xtgee’ in STATA was used to run the regression
models. The following variables were tested in the regres-
sion models; mother’s age (years), mother’s education (years
in school), gravidity (number of pregnancies), parity (num-
ber of term deliveries), hemoglobin (g/dl), quality of life(Karnofsky’s score 1–100), marital status (married, not
married), disclosure of HIV status to partner (no/yes),
partners HIV status (negative, not known, positive), and
self-reported adherence at 6, 12 and 24 months postpartum
(taken as prescribed yes/no). Selection of the mean model
and variance-covariance structure was done based on quasi
likelihood under the independence model criterion (QIC).
Multivariate analysis for drug resistance and mortality were
not performed due to small numbers of mothers with
this endpoint. For both the mean viral load and CD4 cell
change, virologic and immunologic failure models, p-values
less than 0.05 were considered significant.
Ethical approval
The Mitra Plus study protocol was approved by the Insti-
tutional Review Boards of Tanzania; National Institute of
Medical Research (NIMR) NIMR/HQ/R.Sa/Vol.IX/273,
Muhimbili University of Health and Allied Sciences
(MUHAS) reference number MU/01/1022 Vol. VXXII/11
which was also renewed in March 2009 with reference
number MU/RP/AEC/Vol.XIII/20, and Karolinska Institu-
tet, Stockholm, Sweden (reference number 03–404).
Results
Table 1 shows the baseline characteristics at enrolment
for the 84 women included in the mortality analysis out
of whom 73 women were included in the longitudinal
analysis. The median age was 29 years (IQR 25–33), 55%
were officially married and 7 years was the median
length of education. Only 25% had disclosed their HIV
status to a partner or a family member and the majority
(77%) did not know the HIV sero-status of their part-
ners. The majority of the women were clinically classi-
fied as WHO clinical stage 1. The median hemoglobin
concentration was 9.9 g/dL, the median CD4 cell count
was low, 139 cells/μL, and the median viral load was
66,569 copies/mL (Table 1).
Table 2 shows the proportion of women with detectable
viral load (≥400copies/mL) and immunologic failure over a
follow-up period of 24 months after delivery. At enrollment,
97% of the pregnant women had a viral load ≥400copies/mL.
This proportion decreased to 16% three months postpartum
but then increased again to 22% at six months postpartum.
Taking month 3 as the reference, the difference in the pro-
portional viral load increase between month 3 and 6 was
not statistically significant (p = 0.329). The proportion of
women supposed to be on ART for life with detectable
viral load significantly increased with time, to 61% at
12 months (p = 0.000) and 86% (p = 0.000), at 24 months.
The proportion of women with immunologic failure post-
partum also increased significantly to 25% at 12 months
(p = 0.032) and 41% (p = 0.035) at 24 months.
At month 12 postpartum, 42% (25/59) had only viro-
logic failure, 7% (4/59) had only immunologic failure,
Table 1 Baseline characteristics for Mitra Plus women on ART for life
Characteristic All women (n = 84) Analyzed women (n = 73)
Age in years, median (IQR)* 29 (25–32) 29 (25–33)
Education years, median 7 7
Gravidity, median (IQR) 2 (1–3) 2 (2–3)
Parity, median (IQR) 1 (0–2) 1 (0–2)
Hemoglobin median (IQR) 9.9 (8.6-10.9) 9.9 (8.6-10.8)
CD4 count (cell/μL) at enrolment, median(IQR) 139 (95–173) 139 (98–174)
CD4 % at enrolment, median (IQR) 10 (6–13) 11 (6–13)
Viral load, median (IQR) 66,648 (15,253-193,182) 66,569 (15,051-195,289)
10log Viral load mean 10.77 10.73
Karnofsky score, median (IQR) 92 (90–98) 92 (90–100)
WHO clinical stage at enrolment
Stage 1 64/84 (76%) 55/73 (76%)
Stage 2 10/84 (12%) 9/73 (12%)
Stage 3 1/84 (1%) 1/73 (1%)
Stage 4 9/84 (11%) 8/73 (11%)
Marital status
Married 44/84 (52%) 40/73 (55%)
Cohabiting 31/84 (37%) 26/73 (35%)
Not married 9/84 (11%) 7/73 (10%)
Disclosed HIV status to partner/relative
No 69/83 (71%) 54/72 (75%)
Yes 24/83 (29%) 18/72 (25%)
Partner’s HIV status
Negative 10/76 (13%) 10/66 (15%)
Positive 5/76 (7%) 5/66 (8%)
Not known 61/76 (80%) 51/66 (77%)
*(IQR) indicates Inter Quartile Range.
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while 32% (19/59) had neither virologic nor immunologic
failure. At month 24, 46% (26/56) had only virologic failure,
2% (1/56) had only immunologic failure, 39% (22/56) had
both virologic and immunologic failure and 13% (7/56) had
neither virologic nor immunologic failure.
Table 2 also shows women’s self-report on ART adherence
which was 95% (64/68) at 3 months, 85% (56/66) at 6 months,
74% (39/53) at 12 months and 65% (30/46) at 24 months.Table 2 Proportion of women with viral load ≥400 copies/mL
in Mitra Plus women on ART for life
Time
point




Enrolment 71/73 (97%) -
Month 3 11/67 (16%) -
Month 6 15/69 (22%) 8/69 (12%)
Month 12 36/59 (61%) 15/60 (25%)
Month 24 48/56 (86%) 24/58 (41%)At 12 months postpartum, drug resistance mutations
could be detected in 34% of 59 women who were avail-
able for follow-up at this time point, corresponding to
56% (20/36) of all women with detectable viral load.
Among those with detectable drug resistance muta-
tions, 60% (12/20) had resistance to both NRTIs and
NNRTIs while 40% (8/20) had resistance to NNRTIs
only (Table 3). The most common NRTI-associated
mutation was M184V conferring resistance to 3TC,, immunologic failure and self-report on drug adherence
immunologic failure/
d (%)






Table 3 Patterns of reverse transcriptase drug resistance
mutations among women with detectable resistance at
12 months postpartum
Serial Number Subtype NRTI NNRTI
1 U* - K103KN
2 C - K103KN, H221HY
3 A1 - K103KN**
4 A1 M184V KV106A, Y188CWY
5 C - V106A
6 A1 M184V Y181C, H221HY
7 U M184V K101N, Y181C,H221HY
8 A1 M184IM -
9 AI Y181C
10 C M184V Y181C
11 D - Y181CY, Y188CY
12 U - K101Q, E138EGKR
13 A1 - K103N, V108IV
14 CRF10_CD M184V K103N
15 CRF10_CD M184V K103N, M230L
16 U M184V V106AV, G190AG
17 C M184V K101EK, G190A
18 A1 M184V -
19 U M184IMV K103KN, Y181CY
20 A1 M184V Y181CY, H221HY
*U = unclassified.
** = Minor viral population with resistance associated mutation.
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common NNRTI mutations were K103N and Y181C
conferring resistance to NVP which were found in 35%
(7/20) and 30% (6/20) of the women, respectively.
Five women died during the follow up period. One
died one week post delivery and the other four women
died at month 2,5,14 and 24 post delivery. All women
died of HIV-related complications (AIDS). The mortality
rate was 5.9% (95% CI 2.5-13.7%) at 24 months.
Table 4 shows the multivariable analysis by General-
ized Estimated Equations for the associations between
the baseline and clinical characteristics with virologic
failure and immunologic failure using month 3 postpar-
tum as reference. The probability of having virologic
failure increased tenfold among women who reported
non-perfect adherence to ART at month 24 adjusting
for time, age, education, marital status, gravidity, parity,
HIV status disclosure, partner’s HIV status and
hemoglobin concentration (AOR = 10.00; 95% CI: 2.29,
43.66). The probability of immunologic failure was also
significantly associated with self-reported non-adherence,
but the confidence level was very wide due to small
sample size.Discussion
We found an unexpectedly high rate of treatment failure
and drug resistance in this cohort of HIV-infected women
initiated on ART for life during pregnancy in urban Dar es
Salaam, Tanzania. The lowest proportion with virologic
treatment failure (defined as ≥400 copies/mL), 16% was
found 3 months post-delivery, but thereafter increased to
22% at month 6, 61% at month 12 and 86% at 24 months
after delivery. Thus, the great majority of women initiated
on ART during pregnancy failed to stay on treatment
despite needing it for their own health. A high proportion
(56%) of mothers with detectable viral load also had resist-
ance mutations at 12 months postpartum. Despite of this,
there was a significantly lower two-year maternal mortal-
ity rate in this study, 5.9% (95% CI 2.5-13.7%), compared
to the 29.9% (95% CI 13.1-46.9%) mortality rate among
mothers with ≤200 CD4 cells/μL at enrolment in the previ-
ous Petra PMTCT trial at the Dar es Salaam site who only
received short-course ART perinatally [31]. The long-term
mortality rates in the currently analyzed subgroup with
such high failure rates can only be speculated upon.
A review of 89 studies on virologic outcomes among
adult African patients on ART showed an overall treat-
ment success defined as a viral load of <400 copies/mL
of 78% after 6 months of ART, in 76% after 12 months
and in 67% after 24 months [23], but the between study
discrepancies were large, varying from 51% to 97% at
12 months and from 46% to 90% at 24 months [23]. The
6 months virologic failure rate in our study (defined as
detectable viral load ≥400 copies/mL) was similar to that
in the reviewed African studies [23] but higher at 12 and
24 months than in these studies [23]. One possible reason
for the high virologic failure rates at 12 and 24 months
postpartum in the women in the present study could be
that they all participated in a PMTCT study in which
women with CD4 counts ≤ 200 cells/μL who were sup-
posed to continue with ART for life, met women with
CD4 counts >200 cells/μL who stopped ART at 6 months
as per study protocol. The possibility that women shared
information in the waiting room and were influenced by
peers to discontinue ART cannot be excluded. On the
other hand, repeated counseling efforts to promote adher-
ence to life-long ART was carried out at each follow-up
visit, more so than in routine ART care. The fact that
treatment failure increased after 6 months is likely related
to the recommended cessation of breastfeeding at the
same point in time. Efforts to adhere to ART among the
Mitra Plus women put on ART for life were probably
better during the breastfeeding period because women
were highly motivated to prevent transmission of HIV to
their infants, as supported by the drug adherence self-
reports and by qualitative in-depth interviews performed
to explore the reasons for treatment failure among women
who were to stay on life-long ART [32].
Table 4 Generalized Estimated Equation saturated model: Associations between virologic and immunologic failure
with baseline and clinical characteristics
Variable Virologic failure Odds ratio* (OR) 95% CI p-value Immunologic failure Odds ratio* (OR) 95% CI p-value
Month 6 1.54 0.65-3.67 0.329 3.49 0.48-25.66 0.219
Month 12 9.64 2.92-31.86 0.000 6.57 1.17-36.90 0.032
Month 24 45.88 10.07-208.96 0.000 9.78 1.16-81.30 0.035
Age 0.91 0.78-1.05 0.197 0.78 0.47-1.29 0.333
Education 0.92 0.82-1.04 0.191 0.89 0.65-1.00 0.053
Not married 2.88 0.46-17.96 0.257 0.02 0.00-18.35 0.271
Gravidity 1.49 0.68-3.25 0.317 0.86 0.42-1.87 0.746
Parity 0.74 0.30-1.80 0.506 1.08 0.34-3.43 0.898
Disclosed HIV status 0.84 0.17-4.18 0.829 4.94 0.58-42.19 0.144
Partner HIV unknown 0.75 0.19-2.95 0.675 3.63 0.07-181.81 0.519
Partner HIV positive 4.21 0.60-29.38 0.147 1.94 0.03-139.79 0.761
Hemoglobin 0.75 0.54-1.03 0.071 0.32 0.07-1.47 0.143
Not adherent month 6 2.15 0.57-8.09 0.256 2.85 0.20-41.10 0.442
Not adherent month 24 10.01 2.29-43.66 0.002 30.98 1.31-733.91 0.033
*Odds Ratio adjusted for all variables in the table.
Ngarina et al. BMC Infectious Diseases  (2015) 15:175 Page 7 of 10Previous studies of HIV-infected women in resource-
limited countries have found high attrition between diag-
nosis of HIV infection in pregnancy-related services and
initiation of ART among those eligible for ART for life
[33-35]. A meta-analysis on adherence to ART during and
after pregnancy showed that drug adherence was higher
during the antenatal period (74%) compared to postnatal
period (53%) [36]. Long-term follow up in a community-
based ART program in South Africa showed that women
who initiated ART during pregnancy had a significantly
higher risk of loss to follow-up compared to non-pregnant
women [37] while another study from 6 resource-limited
SSA countries found similar retention rates and CD4
count responses in HIV-infected women who initiated
ART during pregnancy and other adults [38].
We defined virologic failure as a viral load ≥400 copies/mL
while previous studies of virologic failure in resource-limited
settings often have used a cut-off of 1000 copies/mL [23].
On the other hand, in most high-income settings, viro-
logic failure is defined as a viral load above 20 HIV-RNA
copies/mL. Had we used the higher cut-off (≥1000 copies/mL)
in our study, the proportion of women with virologic failure at
12 and 24 months postpartum would have remained very
high, 53% and 82%, respectively.
As expected virologic failure preceded immunologic
failure as a warning indicator of treatment failure and was
also associated with self-reported adherence. Several other
African studies have also found that CD4 cell count moni-
toring is a poor indicator for treatment failure [39-43]. A
study in a large ART program in the general population in
Nigeria showed that immunologic criteria missed almost
half of patients with virologic failure [40].In our study, self-reported adherence correlated but
also seriously underestimated the proportion with viro-
logic failure at month 24 postpartum. Several studies
have shown that virologic failure in resource-limited
countries is associated with incomplete adherence
[44-46] and is a strong predictor of resistance [29,44].
Virologic failure has also been shown to be associated
with prior NVP-based PMTCT treatment [45,47]. In our
study 34% of the women had first line drug resistance at
12 months postpartum, which corresponds to 56% of the
women with detectable viral load. Although we did not
conduct any baseline analysis to rule out transmitted
drug resistance, all women in the Mitra Plus study were
treatment naïve. However, a study involving treatment
naïve HIV-infected pregnant mothers in Dodoma and
youth in Dar es Salaam, showed that the prevalence of
ART primary resistant mutations was 11.9% and 9% re-
spectively [48,49]. Assuming similar proportions at base-
line among treatment-naïve women enrolled in our Mitra
Plus study, it is most likely that the high proportion of
drug resistance detectable at 12 months was secondary to
suboptimal drug adherence.
The majority of the women with drug resistance in
our study had multiple resistance mutations, most com-
monly M184V, K103N and Y181C. The same resistant
mutations were also found in infants of women in the
Kisumu PMTCT study [50]. In the Malawi PEPI trial
multiclass drug resistance strains were detected in
29.7% of infants of women who were initiated on anti-
retroviral therapy postpartum [51]. A review of acquired
HIV drug resistance in adults in resource-limited set-
tings, including six studies from SSA showed resistance
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ever, a high frequency of drug resistance after one year
of first line ART similar to that in our study was re-
ported from Cameroon, 46% [52] and Togo 24.5% [53].
A study of HIV-1 drug resistance after first-line ART
failures in six sub-Saharan countries showed that 70%
of those with virologic failure (1000 copies/mL) after
one year of ART had drug resistant mutations [54]. Ac-
cumulation of drug resistance mutations may limit the
response to both first and second- line ART regimens
and lead to the transmission of drug resistant HIV [55].
Despite close monitoring and follow-up as part of our
research study including home visits to all clients who
had missed more than two consecutive appointments,
21% (15/73) of the women on ART for life and eligible
for follow up after delivery did not return for their 24-
month visit. Loss to follow-up and sub-optimal postpar-
tum ART adherence has been major drawbacks to the
efforts of combating MTCT of HIV in resource-limited
regions [33-36]. This makes it pertinent to discuss how
feasible it will be to implement the 2013 WHO guide-
lines to initiate all HIV-positive pregnant women on
ART for life (Option B+). A study done in Malawi,
which was the first country to implement the Option
B+ recommendations, has shown that 17% of women
were already lost to follow-up within six months post-
delivery [56].
Thus, there is a clear need for rapid and affordable
viral load and drug resistance testing and finding feasible
ways to improve drug adherence and minimize loss to
follow-up in resource-limited settings.
The main limitation of this study is the small sample
size limiting us from observing significant associations
so as to draw more firm conclusions. A major strength
of the study is the prospective follow-up for 24 months
and the availability of viral load and drug resistance
information.Conclusions
In summary, our findings show that a very high propor-
tion of Tanzanian HIV-infected women with low CD4
cell count who started ART during pregnancy, failed
virologically after the breastfeeding period with high risk
of drug resistance to standard ART regimens. Counsel-
ing for adherence together with use of viral load assess-
ments to check for adherence and treatment response is
crucial for achieving successful treatment outcomes.
This is especially relevant now when the current WHO
guidelines to start HIV-infected pregnant women on
ART for life irrespective of CD4 cell count in resource-
limited settings (Option B+) are being implemented in
several resource-poor countries in SSA including in
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